Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)

Running, not enrolling · Phase 1

Conditions studied: Hodgkin Disease, Non-Hodgkin Lymphoma, Severe Chronic Active Epstein Barr Virus, T/NK-lymphoproliferative Disease, Nasopharyngeal Carcinoma, Smooth Muscle Tumor

In brief

The subject has a type of cancer or lymph gland disease associated with a virus called Epstein Barr Virus (EBV), which has come back, is at risk of coming back, or has not gone away after standard treatments. This research study uses special immune system cells called LMP, BARF-1 and EBNA1- specific cytotoxic T lymphocytes (MABEL CTLs). Some patients with Lymphoma (such as Hodgkin (HD) or non-Hodgkin Lymphoma (NHL)), T/NK-lymphoproliferative disease, or CAEBV, or solid tumors such as nasopharyngeal carcinoma (NPC), smooth muscle tumors, and leiomyosarcomas show signs of a virus called EBV before or at the time of their diagnosis. EBV causes mononucleosis or glandular fever ("mono" or the "kissing disease"). EBV is found in the cancer cells of up to half the patients with HD and NHL, suggesting that it may play a role in causing Lymphoma. The cancer cells (in lymphoma) and some immune system cells (in CAEBV) infected by EBV are able to hide from the body's immune system and escape destruction. EBV is also found in the majority of NPC and smooth muscle tumors, and some leiomyosarcomas. Investigators want to see if special white blood cells (MABEL CTLs) that have been trained to kill EBV infected cells can survive in patients blood and affect the tumor. In previous studies, EBV CTLs were generated from the blood of the patient, which was often difficult if the patient had recently received chemotherapy. Also, it took up to 1-2 months to make the cells, which is not practical when a patient needs more urgent treatment. To address these issues, the MABEL CTLs were made in the lab in a simpler, faster, and safer way. The MABEL CTLs will still see LMP proteins but also two other EBV proteins called EBNA-1 and BARF. To ensure these cells are available for use in patients in urgent clinical need, investigators have generated MABEL CTLs from the blood of healthy donors and created a bank of these cells, which are frozen until ready for use. Investigators have previously successfully used frozen T cells from healthy donors to treat EBV lymphoma and virus infections and we now have improved our production method to make it faster. In this study, investigators want to find out if they can use banked MABEL CTLs to treat HD, NHL, T/NK-lymphoproliferative disease, CAEBV, NPC, smooth muscle tumors or leiomyosarcoma. Investigators will search the bank to find a MABEL CTL line that is a partial match with the subject. MABEL CTLs are investigational and not approved by the Food and Drug Administration.

Key facts

Study ID: NCT02287311
Run by: Baylor College of Medicine
People needed: 38
Starts: 2015-02-01
Expected to finish: 2029-03-01
Last updated by the study team: 2026-03-23

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

SCREENING
Any patient regardless of age or sex, with diagnosis of either:
EBV positive Hodgkin's lymphoma
EBV Positive non-Hodgkin's Lymphoma (regardless of histologic subtype)
EBV (associated)-T/NK-lymphoproliferative disease
Severe Chronic Active EBV (CAEBV) -- CAEBV is defined as patients with high EBV viral load in plasma or PBMC (>4000 genomes per ug PBMC DNA) and/or biopsy tissue positive for EBV
Other EBV positive malignancies (e.g. nasopharyngeal carcinoma, smooth muscle tumors, etc.)
AND
in first or subsequent relapse (Group A)
with active disease persisting despite therapy (Group B)
with active disease if immunosuppressive chemotherapy is contraindicated e.g. patients who develop Hodgkin disease after solid organ transplantation or if the lymphoma is a second malignancy e.g. a Richter's transformation of CLL. (Group C)
EBV positive tumor
Weighs at least 12kg
Informed consent (and assent as applicable) obtained from patient/guardian.
TREATMENT
Any patient regardless of age or sex, with diagnosis of either:
EBV positive Hodgkin's lymphoma
EBV Positive non-Hodgkin's Lymphoma (regardless of histologic subtype)
EBV (associated)-T/NK-lymphoproliferative disease
Severe Chronic Active EBV (CAEBV) -- CAEBV is defined as patients with high EBV viral load in plasma or PBMC (>4000 genomes per ug PBMC DNA) and/or biopsy tissue positive for EBV
Other EBV positive malignancies (e.g. nasopharyngeal carcinoma, smooth muscle tumors, etc.)
AND
in first or subsequent relapse (Group A)
with active disease persist despite therapy (Group B)
with active disease if immunosuppressive chemotherapy is contraindicated e.g. patients who develop Hodgkin disease after solid organ transplantation or if the lymphoma is a second malignancy e.g. a Richter's transformation of CLL. (Group C)

You may not qualify if…

TREATMENT
Pregnant or lactating
Severe intercurrent infection
Current use of systemic corticosteroids more than 0.5 mg/kg/day
Patients receiving ATG, Campath, or other immunosuppressive T cell monoclonal antibodies within 30 days.

Where it is running

Houston Methodist Hospital — Houston, Texas, United States
Texas Children's Hospital — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.